CL2018002695A1 - Complejos radiofarmacéuticos - Google Patents
Complejos radiofarmacéuticosInfo
- Publication number
- CL2018002695A1 CL2018002695A1 CL2018002695A CL2018002695A CL2018002695A1 CL 2018002695 A1 CL2018002695 A1 CL 2018002695A1 CL 2018002695 A CL2018002695 A CL 2018002695A CL 2018002695 A CL2018002695 A CL 2018002695A CL 2018002695 A1 CL2018002695 A1 CL 2018002695A1
- Authority
- CL
- Chile
- Prior art keywords
- directed
- torio
- fabric
- burner
- complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA INVENCIÓN PROPORCIONA UN MÉTODO PARA LA FORMACIÓN DE UN COMPLEJO DE TORIO DIRIGIDO A TEJIDO, QUE COMPRENDE; A) FORMAR UN QUELADOR OCTADENTADO QUE COMPRENDE CUATRO RESTOS DE HIDROXIPIRIDINONA (HOPO), SUSTITUIDOS EN LA POSICIÓN N CON UN GRUPO METILO Y UN RESTO DE ACOPLAMIENTO QUE TERMINA EN UN GRUPO DE ÁCIDO CARBOXÍLICO; B) ACOPLAR DICHO QUELADOR OCTADENTADO CON AL MENOS UN RESTO DIRIGIDO A TEJIDO QUE APUNTA A HER2; Y C) PONER EN CONTACTO DICHO QUELADOR DIRIGIDO A TEJIDO CON UNA SOLUCIÓN ACUOSA QUE COMPRENDE UN ION DE AL MENOS UN ISÓTOPO DE TORIO EMISOR ALFA. TAMBIÉN SE PROPORCIONAN UN MÉTODO DE TRATAMIENTO DE UNA ENFERMEDAD NEOPLÁSICA O HIPERPLÁSICA QUE COMPRENDE LA ADMINISTRACIÓN DE TAL COMPLEJO DE TORIO DIRIGIDO A TEJIDO, ASÍ COMO EL COMPLEJO Y LAS CORRESPONDIENTES FORMULACIONES FARMACÉUTICAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16162123 | 2016-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018002695A1 true CL2018002695A1 (es) | 2019-01-18 |
Family
ID=55745553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018002695A CL2018002695A1 (es) | 2016-03-24 | 2018-09-24 | Complejos radiofarmacéuticos |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11260136B2 (es) |
| EP (1) | EP3432936A1 (es) |
| JP (2) | JP2019513699A (es) |
| CN (1) | CN108778347A (es) |
| AR (1) | AR107957A1 (es) |
| AU (1) | AU2017239018A1 (es) |
| BR (1) | BR112018069485A2 (es) |
| CA (1) | CA3018607A1 (es) |
| CL (1) | CL2018002695A1 (es) |
| CO (1) | CO2018010024A2 (es) |
| IL (1) | IL261329B (es) |
| JO (1) | JOP20170072B1 (es) |
| MX (1) | MX2018011629A (es) |
| PE (1) | PE20190168A1 (es) |
| SG (2) | SG10202009424TA (es) |
| TW (1) | TWI757273B (es) |
| UA (1) | UA125749C2 (es) |
| UY (1) | UY37167A (es) |
| WO (1) | WO2017162555A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202009424TA (en) * | 2016-03-24 | 2020-11-27 | Bayer Pharma AG | Radio-pharmaceutical complexes |
| US20210187134A1 (en) | 2018-08-28 | 2021-06-24 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
| US20220125960A1 (en) | 2019-02-21 | 2022-04-28 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
| CN121793988A (zh) | 2023-09-13 | 2026-04-03 | 东丽株式会社 | 癌的治疗、预防和/或诊断用药物组合物 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4880615A (en) | 1988-11-25 | 1989-11-14 | Merck & Co., Inc. | Stabilized radiopharmaceutical compositions |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5624901A (en) | 1994-04-15 | 1997-04-29 | The Regents Of The University Of California | 3-hydroxy-2(1H)-pyridinone chelating agents |
| NO312708B1 (no) | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| NO313180B1 (no) | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| US7794691B2 (en) * | 2004-06-25 | 2010-09-14 | The European Community, Represented By The European Commission | Radionuclides for medical use |
| EP1850874B1 (en) * | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| US20090214420A1 (en) * | 2005-04-01 | 2009-08-27 | Medvet Science Pty. Ltd. | Method of Diagnosis and Treatment and Agents Useful for Same |
| US8350011B2 (en) * | 2006-08-04 | 2013-01-08 | Medimmune Limited | Antibodies to ErbB2 |
| US8173800B2 (en) | 2006-08-15 | 2012-05-08 | The Regents Of The University Of California | Luminescent macrocyclic lanthanide complexes |
| AU2010306774A1 (en) * | 2009-10-14 | 2012-05-03 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
| MA41176A (fr) * | 2014-12-17 | 2017-10-24 | Bayer As | Complexes radio-pharmaceutiques |
| SG10202009424TA (en) * | 2016-03-24 | 2020-11-27 | Bayer Pharma AG | Radio-pharmaceutical complexes |
-
2017
- 2017-03-20 SG SG10202009424TA patent/SG10202009424TA/en unknown
- 2017-03-20 US US16/087,040 patent/US11260136B2/en not_active Expired - Fee Related
- 2017-03-20 BR BR112018069485A patent/BR112018069485A2/pt not_active IP Right Cessation
- 2017-03-20 CN CN201780017966.8A patent/CN108778347A/zh active Pending
- 2017-03-20 PE PE2018001861A patent/PE20190168A1/es unknown
- 2017-03-20 WO PCT/EP2017/056503 patent/WO2017162555A1/en not_active Ceased
- 2017-03-20 CA CA3018607A patent/CA3018607A1/en active Pending
- 2017-03-20 JP JP2018547324A patent/JP2019513699A/ja active Pending
- 2017-03-20 UA UAA201810278A patent/UA125749C2/uk unknown
- 2017-03-20 SG SG11201806548UA patent/SG11201806548UA/en unknown
- 2017-03-20 AU AU2017239018A patent/AU2017239018A1/en not_active Abandoned
- 2017-03-20 EP EP17710976.6A patent/EP3432936A1/en not_active Withdrawn
- 2017-03-20 MX MX2018011629A patent/MX2018011629A/es unknown
- 2017-03-21 TW TW106109303A patent/TWI757273B/zh not_active IP Right Cessation
- 2017-03-22 JO JOP/2017/0072A patent/JOP20170072B1/ar active
- 2017-03-23 AR ARP170100720A patent/AR107957A1/es not_active Application Discontinuation
- 2017-03-23 UY UY0001037167A patent/UY37167A/es not_active Application Discontinuation
-
2018
- 2018-08-22 IL IL261329A patent/IL261329B/en active IP Right Grant
- 2018-09-24 CL CL2018002695A patent/CL2018002695A1/es unknown
- 2018-09-24 CO CONC2018/0010024A patent/CO2018010024A2/es unknown
-
2022
- 2022-01-21 US US17/581,808 patent/US20220143229A1/en not_active Abandoned
- 2022-08-30 JP JP2022136797A patent/JP2022173214A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201736389A (zh) | 2017-10-16 |
| BR112018069485A2 (pt) | 2019-07-30 |
| US20220143229A1 (en) | 2022-05-12 |
| IL261329B (en) | 2021-04-29 |
| AU2017239018A1 (en) | 2018-08-16 |
| AR107957A1 (es) | 2018-07-04 |
| WO2017162555A1 (en) | 2017-09-28 |
| PE20190168A1 (es) | 2019-02-01 |
| MX2018011629A (es) | 2019-03-14 |
| UY37167A (es) | 2017-10-31 |
| US11260136B2 (en) | 2022-03-01 |
| US20190091354A1 (en) | 2019-03-28 |
| JP2019513699A (ja) | 2019-05-30 |
| UA125749C2 (uk) | 2022-06-01 |
| IL261329A (en) | 2018-10-31 |
| CA3018607A1 (en) | 2017-09-28 |
| TWI757273B (zh) | 2022-03-11 |
| CN108778347A (zh) | 2018-11-09 |
| JP2022173214A (ja) | 2022-11-18 |
| SG11201806548UA (en) | 2018-08-30 |
| SG10202009424TA (en) | 2020-11-27 |
| JOP20170072B1 (ar) | 2022-03-14 |
| CO2018010024A2 (es) | 2018-10-22 |
| EP3432936A1 (en) | 2019-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018003550A1 (es) | Complejos radio-farmacéuticos. | |
| DOP2017000143A (es) | Complejos radiofarmacéuticos | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| CL2017002727A1 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| CL2018002695A1 (es) | Complejos radiofarmacéuticos | |
| NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| EP2868667A4 (en) | THERAPEUTIC FOR ANEMIA, INCLUDING NICE ENAMA AND CANCER-INDUCED ANEMIA WITH ANTI-BMP9 ANTIBODY AS ACTIVE AGENT | |
| MX2016000405A (es) | Metodos y formulaciones que permiten la modulacion de respuestas inmunitarias relacionadas con la administracion de un farmaco biofarmaceutico. | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| MX379007B (es) | Inhibidor de piridina alquinil prolil hidroxilasa, y metodo de preparacion y uso medico del mismo. | |
| MX2018015022A (es) | Métodos para el tratamiento de la enfermedad de alzheimer. | |
| EA201990093A1 (ru) | Двухкомпонентная композиция | |
| BR112015023078A2 (pt) | inibidores de pirrolopirimindina cdk9 quinase |